Day: August 30, 2023

Backlog Grows to $107.7 Million CALGARY, Alberta, Aug. 30, 2023 (GLOBE NEWSWIRE) — CEMATRIX Corporation (TSXV: CVX) (OTCQB: CTXXF) (“CEMATRIX” or the “Company“) a North American leading manufacturer and supplier of technologically advanced cellular concrete products is pleased to announce its 2023 Contracts have increased by $10.7 million bringing its total contracts announced since the end of the fiscal 2022 year to $37.9 million and $74.9 million since August 3, 2022. Over $40 million of the current backlog is scheduled for 2023, a 37.9% increase compared to total sales of $29 million for the fiscal 2022 year. The $40 million in scheduled 2023 backlog is contracted and a portion of these contracts have already been placed in 2023. The Corporation’s backlog, which is net of sales to the end of July, has...

FDA clearance supported by a clinical study (n=67) and demonstrated treatment safety and efficacy utilizing SUPERB™, 97% of the treated participants in the trial showed improvement in the appearance of acne scars as assessed by masked evaluations Global market value of acne scarring treatment market is expected to cross $4.9 billion by 2029(1)SAN CLEMENTE, Calif. , Aug. 30, 2023 (GLOBE NEWSWIRE) — Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, announced clearance by the U.S. Food and Drug Administration (FDA) for the Company’s 510(k) premarket notification submission to market SUPERB™ for the treatment of acne scars. The approval clears the way for Sofwave™ to expand treatment indication of the Company’s...

MIAMI, Aug. 30, 2023 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndrome (ARDS), today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the H.C. Wainwright 25th Annual Global Investment Conference to be held at the Lotte New York Palace Hotel in New York City on Monday, September 11th, 2023 at 9:00 a.m. ET. A live webcast will be accessible through the Investors section of the Company’s website at www.verupharma.com. Following the event, an archived webcast will be available on the Veru website. About Veru Inc.Veru is a late clinical stage biopharmaceutical company focused on developing novel medicines...

PHOENIX, Aug. 30, 2023 (GLOBE NEWSWIRE) — Clēnera, an Enlight Company (“Enlight”, NASDAQ: ENLT, TASE: ENLT.TA), today announced a 20-year power purchase agreement (“PPA”) with Arizona Public Service (APS), Arizona’s largest utility, for 258 MW of solar and 824 MWh of battery storage at the CO Bar complex outside of Flagstaff, Arizona. The CO Bar complex is a landmark solar and storage complex being developed by Clēnera, a subsidiary of Enlight Renewable Energy. The complex comprising a total of 1.2 GW and 824 MWh of battery storage is expected to be one of the largest renewable energy installations in the United States. “We are excited to work with APS to develop the first combined solar and storage project at the CO Bar complex and help drive Arizona’s clean energy initiatives to deliver affordable, clean power to households in...

WOBURN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) — Bridgeline Digital, Inc. (NASDAQ: BLIN), a leading marketing technology software provider, is pleased to announce its new partnership with Filters Fast, the number one filtration retailer in the United States. Filters Fast will leverage Bridgeline’s HawkSearch AI software to power their search and recommendations engine to grow their revenue strategy. The company selected HawkSearch above other site search tools after recognizing its superior reporting capabilities and seamless integration. HawkSearch, with its RapidUI implementation method, was able to fulfill Filters Fast’s requirements and integrate seamlessly into their custom platform. Based in North Carolina, Filters Fast is the leading online retailer for filtration products in the U.S., offering an extensive catalog...

Additional biomarker data up to two years of treatment continue to demonstrate rapid and sustained normalization of CSF heparan sulfate to normal healthy levels and improvement in lysosomal function biomarkers Additional safety data up to two years of treatment continue to demonstrate that DNL310 is generally well tolerated Previously reported data showed robust and statistically significant reduction of NfL, a marker of neuronal damage, and positive clinical outcome changes in adaptive behavior, cognition, and auditory function Recruitment in the global Phase 2/3 COMPASS study is ongoingSOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment...

SYLA Technologies Announces Sale of Condominium Development Site in Shimo-Meguro, TokyoSYLA Technologies Announces Sale of Condominium Development Site in Shimo-Meguro, TokyoTOKYO, Aug. 30, 2023 (GLOBE NEWSWIRE) — SYLA Technologies Co., Ltd. (NASDAQ: SYT) (“SYLA” or “the Company”), operator of Japan’s largest membership real estate crowd-funding platform, Rimawari-kun, announced its subsidiary, SYLA Co., Ltd. (“SYLA Co.”) has sold a condominium development site in Shimo-Meguro 3-chome, located in Meguro-ku, Tokyo, Japan, on June 30, 2023.As part of SYLA Co.’s real estate development and management strategy, it undertakes third-party projects and provides a comprehensive service for condominium development, leasing, and building management. In September 2021, SYLA Co. obtained a license for its Special Construction Business,...

Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced the publication of a case report highlighting results that demonstrate the potential benefits of using a biological device envelope during reoperative procedures for CIEDs. The report, titled “Rehabilitation of an Existing Device Implant Pocket Using a Biologic Extracellular Matrix Envelope,” was published in the peer-reviewed journal Heart Rhythm Case Reports. The results suggest a biological envelope...